395 related articles for article (PubMed ID: 21903477)
1. Suboccipital steroid injections for transitional treatment of patients with more than two cluster headache attacks per day: a randomised, double-blind, placebo-controlled trial.
Leroux E; Valade D; Taifas I; Vicaut E; Chagnon M; Roos C; Ducros A
Lancet Neurol; 2011 Oct; 10(10):891-7. PubMed ID: 21903477
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of prednisone versus placebo in short-term prevention of episodic cluster headache: a multicentre, double-blind, randomised controlled trial.
Obermann M; Nägel S; Ose C; Sonuc N; Scherag A; Storch P; Gaul C; Böger A; Kraya T; Jansen JP; Straube A; Freilinger T; Kaube H; Jürgens TP; Diener HC; Katsarava Z; Kleinschnitz C; Holle D
Lancet Neurol; 2021 Jan; 20(1):29-37. PubMed ID: 33245858
[TBL] [Abstract][Full Text] [Related]
3. Suboccipital injection with a mixture of rapid- and long-acting steroids in cluster headache: a double-blind placebo-controlled study.
Ambrosini A; Vandenheede M; Rossi P; Aloj F; Sauli E; Pierelli F; Schoenen J
Pain; 2005 Nov; 118(1-2):92-6. PubMed ID: 16202532
[TBL] [Abstract][Full Text] [Related]
4. Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of chronic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study.
Bigal ME; Edvinsson L; Rapoport AM; Lipton RB; Spierings EL; Diener HC; Burstein R; Loupe PS; Ma Y; Yang R; Silberstein SD
Lancet Neurol; 2015 Nov; 14(11):1091-100. PubMed ID: 26432181
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a phase 2, randomised, double-blind, placebo-controlled study.
Dodick DW; Goadsby PJ; Spierings EL; Scherer JC; Sweeney SP; Grayzel DS
Lancet Neurol; 2014 Sep; 13(9):885-92. PubMed ID: 25127173
[TBL] [Abstract][Full Text] [Related]
6. Individualizing treatment with verapamil for cluster headache patients.
Blau JN; Engel HO
Headache; 2004; 44(10):1013-8. PubMed ID: 15546265
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial.
Mulleners WM; Kim BK; Láinez MJA; Lanteri-Minet M; Pozo-Rosich P; Wang S; Tockhorn-Heidenreich A; Aurora SK; Nichols RM; Yunes-Medina L; Detke HC
Lancet Neurol; 2020 Oct; 19(10):814-825. PubMed ID: 32949542
[TBL] [Abstract][Full Text] [Related]
8. Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study.
Bigal ME; Dodick DW; Rapoport AM; Silberstein SD; Ma Y; Yang R; Loupe PS; Burstein R; Newman LC; Lipton RB
Lancet Neurol; 2015 Nov; 14(11):1081-90. PubMed ID: 26432182
[TBL] [Abstract][Full Text] [Related]
9. Trial of Galcanezumab in Prevention of Episodic Cluster Headache.
Goadsby PJ; Dodick DW; Leone M; Bardos JN; Oakes TM; Millen BA; Zhou C; Dowsett SA; Aurora SK; Ahn AH; Yang JY; Conley RR; Martinez JM
N Engl J Med; 2019 Jul; 381(2):132-141. PubMed ID: 31291515
[TBL] [Abstract][Full Text] [Related]
10. Suboccipital steroid injections for cluster headache.
Dodick DW
Lancet Neurol; 2011 Oct; 10(10):867-9. PubMed ID: 21903478
[No Abstract] [Full Text] [Related]
11. Zolmitriptan nasal spray in the acute treatment of cluster headache: a meta-analysis of two studies.
Hedlund C; Rapoport AM; Dodick DW; Goadsby PJ
Headache; 2009 Oct; 49(9):1315-23. PubMed ID: 19788472
[TBL] [Abstract][Full Text] [Related]
12. Botulinum toxin type a for the prophylaxis of chronic daily headache: subgroup analysis of patients not receiving other prophylactic medications: a randomized double-blind, placebo-controlled study.
Dodick DW; Mauskop A; Elkind AH; DeGryse R; Brin MF; Silberstein SD;
Headache; 2005 Apr; 45(4):315-24. PubMed ID: 15836567
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of occipital nerve stimulation for attack prevention in medically intractable chronic cluster headache (ICON): a randomised, double-blind, multicentre, phase 3, electrical dose-controlled trial.
Wilbrink LA; de Coo IF; Doesborg PGG; Mulleners WM; Teernstra OPM; Bartels EC; Burger K; Wille F; van Dongen RTM; Kurt E; Spincemaille GH; Haan J; van Zwet EW; Huygen FJPM; Ferrari MD;
Lancet Neurol; 2021 Jul; 20(7):515-525. PubMed ID: 34146510
[TBL] [Abstract][Full Text] [Related]
14. Effect of Infusion of Calcitonin Gene-Related Peptide on Cluster Headache Attacks: A Randomized Clinical Trial.
Vollesen ALH; Snoer A; Beske RP; Guo S; Hoffmann J; Jensen RH; Ashina M
JAMA Neurol; 2018 Oct; 75(10):1187-1197. PubMed ID: 29987329
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of sphenopalatine ganglion stimulation for chronic cluster headache: a double-blind, randomised controlled trial.
Goadsby PJ; Sahai-Srivastava S; Kezirian EJ; Calhoun AH; Matthews DC; McAllister PJ; Costantino PD; Friedman DI; Zuniga JR; Mechtler LL; Popat SR; Rezai AR; Dodick DW
Lancet Neurol; 2019 Dec; 18(12):1081-1090. PubMed ID: 31701891
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of a Nav1.7 selective sodium channel blocker in patients with trigeminal neuralgia: a double-blind, placebo-controlled, randomised withdrawal phase 2a trial.
Zakrzewska JM; Palmer J; Morisset V; Giblin GM; Obermann M; Ettlin DA; Cruccu G; Bendtsen L; Estacion M; Derjean D; Waxman SG; Layton G; Gunn K; Tate S;
Lancet Neurol; 2017 Apr; 16(4):291-300. PubMed ID: 28216232
[TBL] [Abstract][Full Text] [Related]
17. Recombinant human C1 esterase inhibitor for prophylaxis of hereditary angio-oedema: a phase 2, multicentre, randomised, double-blind, placebo-controlled crossover trial.
Riedl MA; Grivcheva-Panovska V; Moldovan D; Baker J; Yang WH; Giannetti BM; Reshef A; Andrejevic S; Lockey RF; Hakl R; Kivity S; Harper JR; Relan A; Cicardi M
Lancet; 2017 Sep; 390(10102):1595-1602. PubMed ID: 28754491
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of abobotulinumtoxinA for hemiparesis in adults with upper limb spasticity after stroke or traumatic brain injury: a double-blind randomised controlled trial.
Gracies JM; Brashear A; Jech R; McAllister P; Banach M; Valkovic P; Walker H; Marciniak C; Deltombe T; Skoromets A; Khatkova S; Edgley S; Gul F; Catus F; De Fer BB; Vilain C; Picaut P;
Lancet Neurol; 2015 Oct; 14(10):992-1001. PubMed ID: 26318836
[TBL] [Abstract][Full Text] [Related]
19. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial.
Paz-Ares L; de Marinis F; Dediu M; Thomas M; Pujol JL; Bidoli P; Molinier O; Sahoo TP; Laack E; Reck M; Corral J; Melemed S; John W; Chouaki N; Zimmermann AH; Visseren-Grul C; Gridelli C
Lancet Oncol; 2012 Mar; 13(3):247-55. PubMed ID: 22341744
[TBL] [Abstract][Full Text] [Related]
20. Subcutaneous octreotide in cluster headache: randomized placebo-controlled double-blind crossover study.
Matharu MS; Levy MJ; Meeran K; Goadsby PJ
Ann Neurol; 2004 Oct; 56(4):488-94. PubMed ID: 15455406
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
